Report Code : A11929
The increase in the prevalence of cancer patients and surge in demand of hematopoietic transplantation procedures fuels the growth of graft versus host disease Market.
Onkar Sumant - Manager
Life Sciences at Allied Market Research
According to a new report published by Allied Market Research, titled, “Graft Versus Host Disease Market," The graft versus host disease market size was valued at $3.0 billion in 2021, and is estimated to reach $10.4 billion by 2031, growing at a CAGR of 13.5% from 2022 to 2031.
Graft versus host disease is a condition that occurs when donated stem cells or bone marrow (the graft) see the healthy tissues in the patient’s body (the host) as foreign and attack them. It can also occur after an organ transplant. It can cause damage to the host’s tissues and organs, especially the skin, liver, intestines, eyes, mouth, hair, nails, joints, muscles, lungs, kidneys, and genitals. The signs and symptoms may be severe and life threatening. It can occur within the first few months after transplant (acute) or much later (chronic).
Based on when symptoms show up, there are two main types of GVHD. Acute GVHD usually happens within 100 days of the transplant. Chronic GVHD usually appears later, some of the symptoms of acute GVHD are rashes on palms & soles, ears, face, or shoulders, watery diarrhea, abdominal cramps, nausea, vomiting, or lack of appetite, low levels of red blood cells or platelets and fever. Whereas the symptoms of chronic GVHD are dry, irritated eyes & sensitivity to light, joint pain, dryness in mouth, brittle nails, hair loss, and wheezing or persistent cough.
Despite considerable advances in our understanding of the pathophysiology, diagnosis, and predisposing factors for both acute and chronic forms of the disease, a standardized therapeutic strategy still lacks. There is good evidence for initial treatment of both acute and chronic forms of the disease with corticosteroid therapy. Timely diagnosis, multidisciplinary working and good supportive care, including infection prophylaxis, are clearly important in optimizing response and survival in such patients.
Various drugs have been used for the treatment of GVHD, most of these drugs work by damping down (suppressing) the immune system. This stops the donated cells (graft) from attacking your body (host). The patients are at a greater risk of getting an infection if he/she have GVHD, as it weakens the immune system. Treatments for GVHD further increase this risk. Some of the categories of treatment available of GVHD are as follows- steroids, ciclosporin, tacrolimus, light treatment (ECP), monoclonal antibodies, mTOR inhibitor, tyrosine kinase inhibitor, etanercept, thalidomide, pentostatin, methotrexate etc.
The risk of developing GVHD can be lowered by giving the preventive (prophylactic) medicines to suppress the immune system after the transplant. These medicines are anticipated to decrease the ability of the donor's cells to start an immune response against the own tissues. Fungal, bacterial, and viral infections are major risks with this prophylactic medicine regimen, since the immune system is anticipated to be suppressed and have a decreased ability to fight infection. So, the patient is anticipated to be on prophylactic antibiotics, antifungals, and antiviral medicines to decrease infection risks.
Factors that drive growth of the graft versus host disease market size include increase in number of patients with GVHD complication. Many patients return home from transplant centers after haemopoietic cell transplantation (HCT) requiring continued treatment with immunosuppressive drugs. This leads to the increasing demand of immunosuppressive drugs which propels the growth of the graft versus host disease market trends.
For instance, in 2021, VCU Health Hume-Lee Transplant Center performed an astounding 494 transplants. The year before, it was 459. And before that, 434. With a national wait list of 97,392 registrations for kidneys and 11,494 for livers, some people won’t make it long enough to wait for the transplant and needs urgent transplantation requirement.
Surge in development of tissue typing labs and using more precise DNA level tests to select the best HLA matched donor for the patient and increased in R&D process new, and better, methods have been developed to prevent GVHD which are being studied in clinical trials. The use of photopheresis, different immunosuppressive drugs, and new prophylaxis medications given to recipients after transplant are examples of some of that research. Moreover, in May 2019, Incyte Corporation received FDA approval for ruxolitinib (Jakafi) for the treatment of steroid refractory acute graft versus host disease in adult and pediatric patients.
The graft versus host disease market share is segmented on the basis of product, type, end use, and region. On the basis of product, the market is segmented into corticosteroids, monoclonal antibodies, immunosuppressants, and others. On the basis of type, it is segmented into acute and chronic and on the basis of end use the segment is divided into hospital pharmacies, retail pharmacies and online pharmacies.
North America graft versus host disease industry accounted for a majority of the graft versus host disease market share in 2021 and is anticipated to remain dominant during the forecast period. This is attributed due to rise in number of transplantations, increase in number of geriatric populations suffering from liver & kidney disease, presence of key players and advancement in healthcare in the region. Asia-Pacific is anticipated to witness lucrative growth, owing to increase in the GVHD-prevalent population, advancements in the diagnostic measures of the disease, approval of novel treatments, and a greater range of prophylaxis options that are anticipated to lead to significant growth of the market in the near future.
According to Onkar Sumant, Manager, Healthcare at Allied Market Research, “The increase in the prevalence of cancer patients and surge in demand of hematopoietic transplantation procedures fuels the growth of graft versus host disease market analysis.”
Key players operating in the global graft versus host disease market forecast include AbbVie, Accord Healthcare Limited, Asahi Kasei, Bristol Myer Squibb, GlaxoSmithKline PLC, Incyte Corporation, Merck & Co, Novartis, Pfizer and Sanofi.
KEY FINDINGS OF THE STUDY
Talk to David (Europe)
Talk to Sona Padman (Americas)
5933 NE Win Sivers Drive #205,
Portland, OR 97220 United States
Toll Free: +1-800-792-5285
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91 2066346060
Fax: +1(855) 550-5975
Allied Market Research
Contact Toll Free: +1-800-792-5285
Drop us an email at
media@alliedmarketresearch.com
Graft Versus Host Disease Market by Product Type (Corticosteroids, Monoclonal antibodies, Immunosuppressants, Others), by Treatment Type (Acute GVHD, Chronic GVHD), by End Use (Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies): Global Opportunity Analysis and Industry Forecast, 2021-2031
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
Buy Full Version
"Graft Versus Host Disease Market"
Purchase Enquiry
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
Get Industry Data AlertsTo ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of the scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save the time of readers